An early-stage clinical study finds that none of the 25 patients treated developed neurotoxicity or cytokine release syndrome, common hazards of the cancer immunotherapy.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Tumor accessibility, heterogeneity, and microenvironment vary between the two classes of malignancies.

T cells modified to target disease-contributing B cells improved survival in two mouse models of the autoimmune disease.

The manuscript had amassed more than 50 comments about problematic figures and data on PubPeer.

The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.

Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 

Stem-cell–derived natural killer cells engineered in a similar way to CAR-T cells may pave the way to “off the shelf” cancer therapies that aren’t patient-specific.

Drugs approved to treat rheumatoid arthritis block cytokines, the molecules responsible for severe side effects from the immunotherapy, and reduce symptoms in mice.